Showing 1175 Results
Value in Health highlights commentary contributed by NPC's John O'Brien and NPC board member Jan E. Hansen on the implications of the Medicare Drug Price Negotiation Program.
CMS hosted patient-focused listening sessions to discuss the first 10 drugs selected for the Medicare Drug Price Negotiation Program. In this analysis, NPC offers three takeaways to inform how the…
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.